Zum Hauptinhalt springen

Buprenorphin

07. Juli 2019 | Buprenorphin

Erfahrungen nach der Zulassung mit dem wöchentlichen und monatlichen subkutanen Buprenorphin-Depot im Praxisalltag: Fragen an Medical Information und Antworten. (Poster)

Erfahrungen nach der Zulassung mit dem wöchentlichen und monatlichen subkutanen Buprenorphin-Depot im Praxisalltag: Fragen an Medical Information und Antworten. (Poster) Anfragen, die Camurus MIS per E-Mail oder Telefon erhielt, wurden nach Themen…

06. Juli 2019 | Buprenorphin

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men.

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men. Ziaaddini H, Heshmati S, Chegeni M, Mousavi-Ramezanzade M, Mazhari S. Addict Health. 2018 Oct;10(4):269-275. doi: 10.22122/ahj.v10i4.679. https://ww…

06. Juli 2019 | Buprenorphin

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder. Dong R, Wang H, Li D, Lang L, Gray F, Liu Y, Laffont CM, Young M, Jiang J, Liu Z, Learned SM. Dr…

06. Juli 2019 | Buprenorphin

Buvidal®Homepage (im Aufbau)

Buvidal®Homepage (im Aufbau) https://www.buvidal.de/

24. Juni 2019 | Buprenorphin

Indivior Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for SUBOXONE®(buprenorphine and naloxone) Sublingual Film

Indivior Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for SUBOXONE®(buprenorphine and naloxone) Sublingual Film Slough, UK, 18 June 2019–Indivior PLC (LON: INDV) (the ‘Company’), a global…

21. Juni 2019 | Buprenorphin

Buvidal®. Free Clinical Update: Special Edition

Buvidal®. Free Clinical Update: Special Edition This Clinical Update focuses on the new prolonged release subcutaneous buprenorphine injection for opioid use disorder . The purpose of this update is not to summarise the pharmacological proper…

11. Juni 2019 | Buprenorphin

Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.

Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Frost, M., Bailey, G. L., Lintzeris, N., Strang, J., Dunlop, A., Nunes, E. V., Jansen, J. B., Frey…

Weitere Beiträge ansehen

Weitere
akutelle Informationen
zu den Themengebieten